This inventor holds 1 USPTO granted patent. Top assignee: Merck Patent Gmbh. Active years: 2005.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2005
Title: Jörg Stadlmüller: Innovator in Immunoconjugates
Introduction
Jörg Stadlmüller is a notable inventor based in Seeheim, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of immunoconjugates. His work focuses on creating innovative solutions for tumor therapy.
Latest Patents
Stadlmüller holds a patent for immunoconjugates, which are new fusion proteins. These proteins consist of a tumor-associated targeting element, typically a monoclonal antibody or a fragment that recognizes molecules preferentially expressed on human tumor cells, such as the human epidermal growth factor receptor (EGFR). The fusion protein is designed to deliver biologically active ligands, such as growth and differentiation factors, to specific target cells or tissues. This innovative approach has potential applications in tumor therapy.
Career Highlights
Jörg Stadlmüller is associated with Merck Patent GmbH, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on cancer treatment and therapeutic strategies.
Collaborations
Stadlmüller collaborates with esteemed colleagues, including Ilka Von Hoegen and Uwe Hofmann. Their combined expertise contributes to the innovative projects at Merck Patent GmbH.
Conclusion
Jörg Stadlmüller is a pioneering inventor whose work in immunoconjugates represents a significant advancement in tumor therapy. His contributions to biotechnology continue to inspire and drive innovation in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile